var data={"title":"Measles, mumps, and rubella immunization in infants, children, and adolescents","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Measles, mumps, and rubella immunization in infants, children, and adolescents</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/contributors\" class=\"contributor contributor_credentials\">Jan E Drutz, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/contributors\" class=\"contributor contributor_credentials\">Teresa K Duryea, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/contributors\" class=\"contributor contributor_credentials\">Morven S Edwards, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/contributors\" class=\"contributor contributor_credentials\">Mary M Torchia, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jan 22, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1276243470\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Childhood and adolescent immunizations are one of the most effective means of preventing serious illness. Combination measles, mumps, and rubella (MMR) immunization in infants, children, and adolescents will be discussed here, focusing on routine immunization of children in the United States. Our recommendations are consistent with those of the Advisory Committee on Immunization Practices, the American Academy of Pediatrics, and the American Academy of Family Physicians. </p><p>MMR immunization in adults is discussed separately. (See <a href=\"topic.htm?path=measles-mumps-and-rubella-immunization-in-adults\" class=\"medical medical_review\">&quot;Measles, mumps, and rubella immunization in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1276241566\"><span class=\"h1\">MEASLES, MUMPS, AND RUBELLA INFECTIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The measles virus causes an acute infection characterized by fever, cough, coryza, conjunctivitis, rash (<a href=\"image.htm?imageKey=ID%2F57093%7EID%2F57803\" class=\"graphic graphic_picture graphicRef57093 graphicRef57803 \">picture 1A-B</a>), and enanthem (<a href=\"image.htm?imageKey=ID%2F57571\" class=\"graphic graphic_picture graphicRef57571 \">picture 2</a>) that may be followed by severe complications, including encephalitis. (See <a href=\"topic.htm?path=measles-clinical-manifestations-diagnosis-treatment-and-prevention\" class=\"medical medical_review\">&quot;Measles: Clinical manifestations, diagnosis, treatment, and prevention&quot;</a>.)</p><p>The mumps virus causes an acute viral syndrome with parotid swelling (<a href=\"image.htm?imageKey=ID%2F53503\" class=\"graphic graphic_picture graphicRef53503 \">picture 3</a>). Mumps infection usually is self-limited but may be associated with complications, including orchitis and oophoritis, aseptic meningitis, and encephalitis. (See <a href=\"topic.htm?path=mumps#H9\" class=\"medical medical_review\">&quot;Mumps&quot;, section on 'Clinical manifestations'</a>.) </p><p>The rubella virus causes German measles, a generally mild infection with a characteristic rash (<a href=\"image.htm?imageKey=ID%2F61263\" class=\"graphic graphic_picture graphicRef61263 \">picture 4</a>) that can affect both children and adults. However, rubella infection can cause significant birth defects (eg, hearing loss; cataracts (<a href=\"image.htm?imageKey=PEDS%2F64979\" class=\"graphic graphic_picture graphicRef64979 \">picture 5</a>); cardiac disease; and neurodevelopmental effects, including intellectual disability and autism) if it occurs early in fetal life. (See <a href=\"topic.htm?path=rubella#H7\" class=\"medical medical_review\">&quot;Rubella&quot;, section on 'Clinical manifestations'</a> and <a href=\"topic.htm?path=rubella-in-pregnancy\" class=\"medical medical_review\">&quot;Rubella in pregnancy&quot;</a> and <a href=\"topic.htm?path=congenital-rubella-syndrome-clinical-features-and-diagnosis#H8\" class=\"medical medical_review\">&quot;Congenital rubella syndrome: Clinical features and diagnosis&quot;, section on 'Clinical features'</a>.)</p><p class=\"headingAnchor\" id=\"H1276241676\"><span class=\"h1\">VACCINE FORMULATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Two formulations of measles, mumps, and rubella-containing vaccines are available in the United States [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/1\" class=\"abstract_t\">1</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Measles, mumps, and rubella combination vaccine (MMR) &ndash; MMR is a live attenuated vaccine that includes measles (Edmonston-Enders vaccine strain), mumps (Jeryl-Lynn vaccine strain), and rubella (Wistar RA <span class=\"nowrap\">27/3</span> vaccine strain). It is licensed for routine use in individuals &ge;12 months of age and for infants &ge;6 months of age who are traveling internationally.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Measles, mumps, rubella, and varicella combination vaccine (MMRV) &ndash; MMRV is a live attenuated vaccine that includes measles (Edmonston-Enders strain), mumps (Jeryl-Lynn vaccine strain), rubella (Wistar RA <span class=\"nowrap\">27/3</span> vaccine strain), and varicella (Oka strain). It is licensed for use in children 12 months through 12 years of age.</p><p/><p>Both vaccines contain small amounts of <a href=\"topic.htm?path=neomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">neomycin</a> and gelatin [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/1\" class=\"abstract_t\">1</a>]. They are supplied as a lyophilized (freeze-dried) powder with a separate diluent. Proper storage and handling of MMR and MMRV powder and diluents is necessary to prevent inactivation of the vaccine viruses [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/1\" class=\"abstract_t\">1</a>]. MMR and MMRV have different storage requirements (<a href=\"image.htm?imageKey=PEDS%2F101587\" class=\"graphic graphic_table graphicRef101587 \">table 1</a>).</p><p>Single antigen (ie, monovalent) formulations of measles, mumps, and rubella vaccines are not available in the United States [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/2\" class=\"abstract_t\">2</a>] but continue to be available in other countries. An investigational monovalent aerosolized measles vaccine resulted in lower rates of seropositivity than a subcutaneously administered vaccine in a randomized trial in Indian children [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/3\" class=\"abstract_t\">3</a>].</p><p class=\"headingAnchor\" id=\"H1787931404\"><span class=\"h1\">CHOICE OF VACCINE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The routine schedule for measles, mumps, and rubella vaccine (MMR) is the same as that for <a href=\"topic.htm?path=varicella-virus-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">varicella vaccine</a> (<a href=\"image.htm?imageKey=PEDS%2F82617\" class=\"graphic graphic_figure graphicRef82617 \">figure 1</a>). For children who require both MMR and varicella vaccine, the decision to use combination MMR and varicella vaccine (MMRV) or separate MMR and varicella vaccines should be made on a case-by-case basis after a discussion of the risks and benefits of each strategy with the child's parents [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/1\" class=\"abstract_t\">1</a>]. The <a href=\"https://www.cdc.gov/vaccines/vpd/mmr/hcp/vacopt-factsheet-hcp.html&amp;token=tF/G0g1G66lNQera+j9XUF4fWh/lQiyTIeZllJcizjVYAgP/eAMLAiLv8mGQqm8r5bb89QNMwj6/zrqfAttC5ZODP7s1imVWU7kg3VvM0ds=&amp;TOPIC_ID=101273\" target=\"_blank\" class=\"external\">Centers for Disease Control and Prevention</a> (CDC) provides information and a fact sheet to help parents understand their options. (See <a href=\"#H1276242324\" class=\"local\">'Adverse effects'</a> below.)</p><p>In agreement with the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Pediatrics (AAP), if the parents do not have a preference [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/1,4\" class=\"abstract_t\">1,4</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For the <strong>first</strong> doses of measles, mumps, rubella, and varicella vaccines:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>We suggest separate MMR and varicella vaccines (ie, administered at the same visit, but at different sites) for children 12 through 47 months of age</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>We suggest MMRV for children 48 months through 12 years of age</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For the <strong>second</strong> doses of measles, mumps, rubella, and varicella vaccines:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>We suggest MMRV for children between 15 months and 12 years of age</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>We suggest separate measles, mumps, rubella, and varicella vaccines for children &ge;13 years of age</p><p/><p>The immunogenicity of MMRV is similar to that of immunization with MMR and varicella vaccines at separate injection sites, whether MMRV is administered for the first, second, or both doses [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/5\" class=\"abstract_t\">5</a>]. However, the risk of febrile seizures is increased when MMRV is administered for the first dose in children &lt;4 years of age, although the absolute risk of febrile seizures remains low (approximately 1 per 3000 to 4000 doses of MMR) [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/6-8\" class=\"abstract_t\">6-8</a>]. In several large postlicensure studies, MMRV was associated with an approximately twofold increased risk of febrile seizures one to two weeks after immunization compared with separate injections of MMR and varicella (<a href=\"image.htm?imageKey=PEDS%2F65930\" class=\"graphic graphic_table graphicRef65930 \">table 2</a>) [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/9-11\" class=\"abstract_t\">9-11</a>]. In another large postlicensure study, neither MMRV nor separate injections of MMR and <a href=\"topic.htm?path=varicella-virus-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">varicella vaccine</a> was associated with an increased risk of febrile seizures at age 4 to 6 years [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/12\" class=\"abstract_t\">12</a>].</p><p class=\"headingAnchor\" id=\"H1276243721\"><span class=\"h1\">INDICATIONS AND SCHEDULES</span></p><p class=\"headingAnchor\" id=\"H1787929993\"><span class=\"h2\">United States</span></p><p class=\"headingAnchor\" id=\"H1787930105\"><span class=\"h3\">Routine immunization</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In the United States, routine immunization with measles, mumps, and rubella vaccine (MMR) is recommended for children at 12 to 15 months and 4 through 6 years of age (<a href=\"image.htm?imageKey=PEDS%2F82617\" class=\"graphic graphic_figure graphicRef82617 \">figure 1</a>) [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/1\" class=\"abstract_t\">1</a>].</p><p>However, the second dose of MMR can be given as early as 28 days after the first dose, provided that both doses are given at &ge;12 months of age [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/1\" class=\"abstract_t\">1</a>]. The first and second doses of varicella-containing vaccines should be separated by at least three months. However, if the second dose is administered at least 28 days after the first dose, the second dose does not need to be repeated [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/13\" class=\"abstract_t\">13</a>].</p><p>Routine immunization is initiated at 12 to 15 months to permit decline of passively acquired maternal measles antibody, which interferes with the immune response [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/14,15\" class=\"abstract_t\">14,15</a>]. In a prospective randomized trial, antimeasles antibody developed in 87 percent of children vaccinated at 9 months, 95 percent of those vaccinated at 12 months, and 98 percent of those vaccinated at 15 months of age [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/14\" class=\"abstract_t\">14</a>]. In several studies, the median seroconversion rates for measles, mumps, and rubella after one dose of MMR were &ge;94 percent; immunity appears to be long-lasting (<a href=\"image.htm?imageKey=PEDS%2F101589\" class=\"graphic graphic_table graphicRef101589 \">table 3</a>) [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/16-25\" class=\"abstract_t\">16-25</a>].</p><p>Delay of the first dose of MMR beyond age 12 to 15 months increases the duration of susceptibility and contributed to large measles outbreaks in the United States during the late 1980s and early 1990s [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/26-29\" class=\"abstract_t\">26-29</a>]. Delay of the first dose of MMR beyond 15 months of age has also been associated with an increased risk of seizures in the 7 to 10 days after immunization [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/30,31\" class=\"abstract_t\">30,31</a>]. In a cohort of 840,348 children, the relative risk of seizures 7 to 10 days after the first dose of measles-containing vaccine compared with the control interval (days 0 to 6 and 11 to 42) was 6.5 (95% CI 5.3-8.1) among those 16 to 23 months of age compared with 3.4 (95% CI 3.0-3.9) among those 12 to 15 months [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/30\" class=\"abstract_t\">30</a>]. (See <a href=\"#H1276242324\" class=\"local\">'Adverse effects'</a> below.)</p><p>The second dose of MMR may elicit an antibody response in children who do not respond to the first dose. Nearly all children who do not respond to the first dose of MMR respond to the second [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/32,33\" class=\"abstract_t\">32,33</a>]. The second dose is routinely administered before school entry (four to six years) because the risk of measles is greater in school-age than in preschool children and the risk of adverse events is lower at four to six years than in older children [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/34\" class=\"abstract_t\">34</a>].</p><p>A third dose of MMR is not routinely recommended but may be warranted during a mumps outbreak. In an observational study, provision of a third dose of MMR to young adults was not associated with any more protection against measles than two doses [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/35\" class=\"abstract_t\">35</a>]. (See <a href=\"#H1787932314\" class=\"local\">'Outbreaks and international travel'</a> below.)</p><p>Routine MMR immunization is effective in preventing measles, mumps, and rubella infection, as indicated by the dramatic decline in the number of cases of measles, mumps, and rubella following the introduction of vaccine programs in the 1960s (<a href=\"image.htm?imageKey=PEDS%2F101586%7EPEDS%2F101590%7EPEDS%2F70446\" class=\"graphic graphic_figure graphicRef101586 graphicRef101590 graphicRef70446 \">figure 2A-C</a>) [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/1,36\" class=\"abstract_t\">1,36</a>]. Endemic rubella and congenital rubella syndrome were eliminated from the United States in 2005 and from the rest of the Americas in 2015 [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/37,38\" class=\"abstract_t\">37,38</a>]. However, sporadic cases of rubella continue to be reported in the United States, particularly among immigrant populations [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/39,40\" class=\"abstract_t\">39,40</a>]. Outbreaks of measles continue to occur, largely in unvaccinated individuals [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/41-45\" class=\"abstract_t\">41-45</a>]. Outbreaks of mumps in vaccinated populations raise concern about waning immunity. (See <a href=\"topic.htm?path=rubella#H4\" class=\"medical medical_review\">&quot;Rubella&quot;, section on 'United States'</a> and <a href=\"topic.htm?path=measles-epidemiology-and-transmission#H4\" class=\"medical medical_review\">&quot;Measles: Epidemiology and transmission&quot;, section on 'United States'</a> and <a href=\"topic.htm?path=mumps#H2480787895\" class=\"medical medical_review\">&quot;Mumps&quot;, section on 'Outbreaks'</a>.)</p><p>The introduction of measles immunization programs has been associated with decreased childhood mortality from nonmeasles infectious diseases [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/46-51\" class=\"abstract_t\">46-51</a>], perhaps by preventing the loss of immune memory cells that occurs with natural measles infection [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/52,53\" class=\"abstract_t\">52,53</a>].</p><p class=\"headingAnchor\" id=\"H1787932314\"><span class=\"h3\">Outbreaks and international travel</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Early administration of the first <span class=\"nowrap\">and/or</span> second dose of MMR is recommended for children living in or traveling to areas where there is a measles outbreak (defined as &ge;3 cases linked in time and space) and children traveling outside the United States [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/1,54\" class=\"abstract_t\">1,54</a>]. The Centers for Disease Control and Prevention maintains a current list <a href=\"http://www.cdc.gov/measles/cases-outbreaks.html&amp;token=mjmpv7xMHRIW2nr+3NCnsdwBGrBI4zYnqDgrZg6MhNHNsi3iOiz0wO9YlZ480JRL5GrZpu3OBvJezb969YzCvw==&amp;TOPIC_ID=101273\" target=\"_blank\" class=\"external\">of measles cases and outbreaks</a> in the United States. (See <a href=\"topic.htm?path=immunizations-for-travel#H3181096\" class=\"medical medical_review\">&quot;Immunizations for travel&quot;, section on 'Measles, mumps, and rubella'</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a <strong>measles</strong> outbreak setting or before departure for international travel [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/1,54\" class=\"abstract_t\">1,54</a>]:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Children 6 through 11 months should receive one dose of MMR. Children who receive the first dose of MMR before age 12 months should receive two additional doses, separated by at least 28 days, beginning at age 12 to 15 months.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Children &ge;12 months of age should receive two doses of MMR separated by at least 28 days, with the first dose administered on or after the first birthday.</p><p/><p class=\"bulletIndent1\">In observational studies during measles outbreaks, administration of MMR to infants &ge;6 months of age was well tolerated [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/55\" class=\"abstract_t\">55</a>] and as immunogenic and effective as a single dose of MMR administered to children &ge;12 months [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/55-57\" class=\"abstract_t\">55-57</a>]. In addition, no major safety concerns were identified in a review of reports to the Vaccine Adverse Event Reporting System regarding administration of MMR or MMRV to infants &lt;9 months of age [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/58\" class=\"abstract_t\">58</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a <strong>mumps</strong> outbreak setting, children who are incompletely immunized against mumps should receive age-appropriate immunization. (See <a href=\"#H1787930123\" class=\"local\">'Catch-up immunization'</a> below.)</p><p/><p class=\"bulletIndent1\">In addition, children who previously received two doses of mumps-containing vaccine and are identified by public health authorities as being at increased risk (eg, intense exposure setting) of mumps in an outbreak should receive a third dose of mumps-containing vaccine [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/59\" class=\"abstract_t\">59</a>]. (See <a href=\"topic.htm?path=mumps#H31\" class=\"medical medical_review\">&quot;Mumps&quot;, section on 'Prevention'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H1787930117\"><span class=\"h3\">Postexposure prophylaxis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Postexposure prophylaxis with MMR vaccine or <a href=\"topic.htm?path=immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information\" class=\"drug drug_pediatric\">immune globulin</a> may prevent or modify the clinical course of measles in children who are nonimmune [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/1\" class=\"abstract_t\">1</a>]. In observational studies, the effectiveness of measles postexposure prophylaxis ranges from 69 to 100 percent for immune<strong> </strong>globulin administered intramuscularly (IGIM) and 83 to 100 percent for MMR vaccine [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/60-65\" class=\"abstract_t\">60-65</a>].</p><p>For mumps and rubella, neither MMR vaccine nor <a href=\"topic.htm?path=immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information\" class=\"drug drug_pediatric\">immune globulin</a> is effective for postexposure prophylaxis [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/1,66,67\" class=\"abstract_t\">1,66,67</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Choice of regimen for measles postexposure prophylaxis</strong> &ndash; Options for measles postexposure prophylaxis for children vary according to age, time of exposure, and contraindications to MMR vaccine [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/1,54\" class=\"abstract_t\">1,54</a>]:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Infants 0 through 5 months of age </strong>&ndash; Infants 0 through 5 months of age who are exposed to measles should receive IGIM 0.5 <span class=\"nowrap\">mL/kg</span> (maximum dose 15 mL) or intravenous <a href=\"topic.htm?path=immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information\" class=\"drug drug_pediatric\">immune globulin</a> (IVIG) 400 <span class=\"nowrap\">mg/kg</span> within six days of exposure [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/1\" class=\"abstract_t\">1</a>]. </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Infants 6 through 11 months of age </strong>&ndash; Infants aged 6 through 11 months may receive either MMR vaccine within 72 hours of exposure or IGIM 0.5 <span class=\"nowrap\">mL/kg</span> (maximum dose 15 mL) or IVIG 400 <span class=\"nowrap\">mg/kg</span> within six days of exposure [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/1\" class=\"abstract_t\">1</a>].</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Children &ge;12 months of age</strong> &ndash; MMR vaccine is preferred to IGIM or IVIG for postexposure prophylaxis in vaccine-eligible children &ge;12 months of age who have been exposed to measles virus within the previous 72 hours [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/1\" class=\"abstract_t\">1</a>].</p><p/><p class=\"bulletIndent2\">Those whose exposure occurred &ge;72 hours and &lt;6 days previously should receive IGIM 0.5 <span class=\"nowrap\">mL/kg</span> (maximum dose 15 mL) or IVIG 400 <span class=\"nowrap\">mg/kg</span> if they have not received at least one dose of MMR at &ge;12 months of age. For children who weigh &gt;30 kg, the maximum dose of IGIM (15 mL) may be effective, even though it is less than the recommended dose of 0.5 <span class=\"nowrap\">mL/kg</span> [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/68\" class=\"abstract_t\">68</a>].</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Children with contraindications to MMR vaccine </strong>&ndash; For children with contraindications to MMR (<a href=\"image.htm?imageKey=PEDS%2F101585\" class=\"graphic graphic_table graphicRef101585 \">table 4</a>), IVIG 400 <span class=\"nowrap\">mg/kg</span> rather than IGIM is recommended [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/54\" class=\"abstract_t\">54</a>]. (See <a href=\"#H1787928363\" class=\"local\">'Contraindications'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Subsequent management</strong> &ndash; Infants who receive a dose of MMR vaccine at 6 through 11 months of age should receive two additional doses, separated by at least 28 days, beginning at age 12 to 15 months.</p><p/><p class=\"bulletIndent1\">Any nonimmune individual exposed to measles who received <a href=\"topic.htm?path=immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information\" class=\"drug drug_pediatric\">immune globulin</a> should subsequently receive MMR vaccine no earlier than six months after IGIM or eight months after IVIG (<a href=\"image.htm?imageKey=PEDS%2F72640\" class=\"graphic graphic_table graphicRef72640 \">table 5</a>), provided the individual is then &ge;12 months of age and the vaccine is not otherwise contraindicated. (See <a href=\"#H1276241973\" class=\"local\">'Recent receipt of blood or immune globulin'</a> below.)</p><p/><p class=\"headingAnchor\" id=\"H1787930123\"><span class=\"h3\">Catch-up immunization</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Catch-up MMR immunization is necessary for children who lack appropriate evidence of immunity or whose MMR immunization status is unknown [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/1\" class=\"abstract_t\">1</a>]. In children and adolescents in the United States, evidence of immunity is established by one of the following [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/1\" class=\"abstract_t\">1</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Documentation of age-appropriate vaccination with a live attenuated vaccine; parent- or caregiver-reported doses are not valid without appropriate documentation:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For measles &ndash; Two doses of measles-containing vaccine, both administered at &ge;12 months of age, separated by &ge;28 days (doses administered before 12 months of age are not counted)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For mumps &ndash; Two doses of mumps-containing vaccine, both administered at &ge;12 months of age, separated by &ge;28 days (doses administered before 12 months of age are not counted)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For rubella &ndash; One dose of rubella-containing vaccine administered at &ge;12 months of age, except for pregnant women; evidence of rubella immunity in pregnant females is discussed separately (see <a href=\"topic.htm?path=immunizations-during-pregnancy#H5\" class=\"medical medical_review\">&quot;Immunizations during pregnancy&quot;, section on 'Preconception immunization'</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Although serologic testing is not necessary before catch-up MMR immunization, individuals who have documented laboratory evidence of immunity (measles, mumps, and rubella immunoglobulin G) do not require catch-up immunization.</p><p/><p class=\"bulletIndent1\">Revaccination is not necessary for individuals who have documentation of age-appropriate vaccination but lack serologic evidence of immunity, <strong>except</strong> for women of childbearing age who are not immune to rubella; such women should receive one additional dose of MMR (maximum of three doses) but need not be retested for serologic evidence of immunity.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Laboratory confirmation of measles, mumps, or rubella disease &ndash; Clinical diagnosis without laboratory confirmation is insufficient evidence of immunity.</p><p/><p>In observational studies, administration of a third dose of MMR has not been associated with increased rates of adverse effects [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/69-71\" class=\"abstract_t\">69-71</a>].</p><p>The catch-up regimen for MMR varies with age, the number of previous doses administered at &ge;12 months of age, and whether or not <a href=\"topic.htm?path=varicella-virus-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">varicella vaccine</a> is needed (<a href=\"image.htm?imageKey=PEDS%2F101591\" class=\"graphic graphic_table graphicRef101591 \">table 6</a>).</p><p class=\"headingAnchor\" id=\"H1787929999\"><span class=\"h2\">Other countries</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"http://www.who.int/immunization/policy/position_papers/measles/en/&amp;token=sfCvcJm3JRDa+kDUMy71/sMbZ/iu4BJ4YDILPdHSsKMy8nOtFMzY1YrPCYXfXzNr9Ps5sU0mVaAtVuMeXWIZsUy2zQ2JCE1uYJqoHh/rKuQ=&amp;TOPIC_ID=101273\" target=\"_blank\" class=\"external\">The World Health Organization</a> (WHO) recommends:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Vaccination against measles for all susceptible children and adults [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/72\" class=\"abstract_t\">72</a>]; the first dose of measles vaccine is recommended at age 9 months for children from countries with ongoing measles transmission and at age 12 months for children from countries with low levels of measles transmission</p><p/><p class=\"bulletIndent1\">WHO recommendations for postexposure prophylaxis for individuals with contraindications to measles vaccine (eg, age &lt;6 months) are similar to those in the United States. (See <a href=\"#H1787930117\" class=\"local\">'Postexposure prophylaxis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Vaccination against mumps in countries with a well-established childhood vaccination program and the capacity to maintain high levels of vaccination coverage, and where the reduction of mumps incidence is a public health priority [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/73\" class=\"abstract_t\">73</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Introduction of rubella-containing vaccines in conjunction with accelerated measles control and elimination activities [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/74\" class=\"abstract_t\">74</a>]</p><p/><p>Routine immunization schedules vary from country to country. Schedules for individual countries are available through the <a href=\"http://apps.who.int/immunization_monitoring/globalsummary&amp;token=OwnNIPPeGk/rbsSIEMq0IgOjNOv7VUbbhIG6Z6gMcV0Dql41+3EEqSmN6lmXxVXDaQVNaZmvR6hPn+vQ/s4dzQ==&amp;TOPIC_ID=101273\" target=\"_blank\" class=\"external\">WHO</a>.</p><p>Global measles vaccination is estimated to have prevented more than 20 million deaths during 2000 to 2015; during the same time period, measles incidence decreased from 146 to 36 cases per million population [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/75\" class=\"abstract_t\">75</a>].</p><p class=\"headingAnchor\" id=\"H2313247273\"><span class=\"h1\">ADMINISTRATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Measles, mumps, and rubella combination vaccine (MMR) and measles, mumps, rubella, and varicella combination vaccine (MMRV) are supplied as a lyophilized (freeze-dried) powder with a separate diluent. Only the diluent that is supplied with the vaccine should be used to reconstitute it; any dose of vaccine that is reconstituted with the incorrect diluent should be repeated.</p><p>The dose of MMR and MMRV is 0.5 mL [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/76\" class=\"abstract_t\">76</a>]. MMR and MMRV are administered subcutaneously with a <span class=\"nowrap\">5/8</span> inch (1.6 cm), 23- to 25-guage needle. The site of administration varies with age: usually the upper outer triceps for children &ge;12 months of age and the lateral thigh for infants &lt;12 months of age. Doses that were administered intramuscularly (IM) need not be repeated. Immunogenicity appears to be similar with IM subcutaneous administration [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/77\" class=\"abstract_t\">77</a>].</p><p>MMR may be administered at the same clinic visit as other routine childhood immunizations [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/78,79\" class=\"abstract_t\">78,79</a>]. However, if injectable or nasally administered live attenuated vaccines (eg, MMR, varicella, live attenuated influenza, yellow fever) are not administered at the same clinic visit, they should be separated by &ge;28 days [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/76\" class=\"abstract_t\">76</a>]. Administration at &lt;28 days may impair the immune response to one of the vaccines [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/80-82\" class=\"abstract_t\">80-82</a>]. Live attenuated oral vaccines (eg, <a href=\"topic.htm?path=rotavirus-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">rotavirus vaccine</a>, oral <a href=\"topic.htm?path=typhoid-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">typhoid vaccine</a>) can be administered at the same time as or at any interval before or after other live vaccines (<a href=\"image.htm?imageKey=ID%2F112956\" class=\"graphic graphic_table graphicRef112956 \">table 7</a>) [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/76\" class=\"abstract_t\">76</a>].</p><p class=\"headingAnchor\" id=\"H1787928363\"><span class=\"h1\">CONTRAINDICATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Contraindications to administration of measles, mumps, and rubella vaccine (MMR) include (<a href=\"image.htm?imageKey=PEDS%2F101585\" class=\"graphic graphic_table graphicRef101585 \">table 4</a>) [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/1\" class=\"abstract_t\">1</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Severe allergic reaction (eg, anaphylaxis) after a previous dose of MMR or <a href=\"topic.htm?path=varicella-virus-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">varicella vaccine</a> (for combined MMR varicella vaccine [MMRV]), or to a vaccine component (eg, <a href=\"topic.htm?path=neomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">neomycin</a>, gelatin). (See <a href=\"topic.htm?path=allergic-reactions-to-vaccines\" class=\"medical medical_review\">&quot;Allergic reactions to vaccines&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pregnancy or attempting to become pregnant &ndash; Women should be counseled to avoid becoming pregnant for 28 days after MMR because of the theoretic risk of congenital rubella syndrome [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/1\" class=\"abstract_t\">1</a>]. However, it is not necessary to perform a pregnancy test before administering MMR to a female adolescent if the she reports that she is not pregnant and is not trying to become pregnant. (See <a href=\"topic.htm?path=rubella-in-pregnancy\" class=\"medical medical_review\">&quot;Rubella in pregnancy&quot;</a> and <a href=\"topic.htm?path=immunizations-during-pregnancy#H262425104\" class=\"medical medical_review\">&quot;Immunizations during pregnancy&quot;, section on 'Measles, mumps, rubella'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Immunodeficiency [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/1,83\" class=\"abstract_t\">1,83</a>] &ndash; Individuals with immunodeficiency are at risk for severe complications following immunization with live attenuated virus vaccines (eg, encephalitis, pneumonitis) [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/84-88\" class=\"abstract_t\">84-88</a>]. Immune deficiencies that are contraindications to MMR or MMRV include:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Primary or acquired immunodeficiency (eg, cellular immunodeficiency, hypogammaglobulinemia, HIV infection with severe immune suppression)</p><p/><p class=\"bulletIndent2\">HIV infection with severe immunosuppression is defined as CD4+ T lymphocyte [CD4] percentage &lt;15 percent at any age or, if CD4 percentage not available [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/83,89\" class=\"abstract_t\">83,89</a>]:</p><p/><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>CD4 count <span class=\"nowrap\">&lt;750/microL</span> for children &le;12 months of age</p><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>CD4 count <span class=\"nowrap\">&lt;500/microL</span> for children one through five years of age</p><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>CD4 count <span class=\"nowrap\">&lt;200/microL</span> for children &gt;5 years of age</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Blood dyscrasia, leukemia, lymphoma, or other malignant neoplasms affecting the bone marrow or lymphatic system.</p><p/><p class=\"bulletIndent2\">The use of MMR in patients with cancer and in the pre- and posttransplant setting for solid organ and allogeneic hematopoietic cell transplant recipients is discussed separately. (See <a href=\"topic.htm?path=immunizations-in-adults-with-cancer\" class=\"medical medical_review\">&quot;Immunizations in adults with cancer&quot;</a> and <a href=\"topic.htm?path=immunizations-in-solid-organ-transplant-candidates-and-recipients\" class=\"medical medical_review\">&quot;Immunizations in solid organ transplant candidates and recipients&quot;</a> and <a href=\"topic.htm?path=immunizations-in-hematopoietic-cell-transplant-candidates-and-recipients\" class=\"medical medical_review\">&quot;Immunizations in hematopoietic cell transplant candidates and recipients&quot;</a>.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Systemic immunosuppressive therapy, including large daily doses of corticosteroids (equivalent to &ge;2 <span class=\"nowrap\">mg/kg</span> per day or &ge;20 mg per day of <a href=\"topic.htm?path=prednisone-pediatric-drug-information\" class=\"drug drug_pediatric\">prednisone</a> for persons who weigh &gt;10 kg) for &ge;14 consecutive days [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/90\" class=\"abstract_t\">90</a>]; MMR should be avoided for at least one month after high-dose corticosteroid therapy.</p><p/><p class=\"bulletIndent2\">Lower doses of systemic corticosteroids, maintenance physiologic doses (ie, replacement therapy), and local corticosteroid injections (eg, joint, tendon) are <strong>not</strong> a contraindication to MMR [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/90\" class=\"abstract_t\">90</a>].</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Family history of congenital or hereditary immunodeficiency in parents or siblings <strong>unless</strong> the immune competence of the vaccine recipient has been substantiated clinically or verified in a laboratory.</p><p/><p class=\"headingAnchor\" id=\"H1276243647\"><span class=\"h1\">SPECIAL CIRCUMSTANCES</span></p><p class=\"headingAnchor\" id=\"H1276241973\"><span class=\"h2\">Recent receipt of blood or immune globulin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The receipt of parenterally administered <a href=\"topic.htm?path=immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information\" class=\"drug drug_pediatric\">immune globulin</a> or antibody-containing blood products can blunt or block the host response to certain live-virus vaccines. For most children and adolescents, the suggested interval between receipt of immune globulin or antibody containing blood products and administration of measles, mumps, and rubella combination vaccine (MMR) varies between 3 and 11 months depending upon the product (<a href=\"image.htm?imageKey=PEDS%2F72640\" class=\"graphic graphic_table graphicRef72640 \">table 5</a>) [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/76,91,92\" class=\"abstract_t\">76,91,92</a>].</p><p>Postpartum administration of MMR to women who received anti-D (Rho) <a href=\"topic.htm?path=immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information\" class=\"drug drug_pediatric\">immune globulin</a> or blood products during the last trimester of pregnancy or at delivery is discussed separately. (See <a href=\"topic.htm?path=immunizations-during-pregnancy#H35\" class=\"medical medical_review\">&quot;Immunizations during pregnancy&quot;, section on 'Postpartum immunization'</a>.)</p><p>If <a href=\"topic.htm?path=immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information\" class=\"drug drug_pediatric\">immune globulin</a> or blood products must be given within 14 days after administration of MMR, another dose of the vaccine should be administered after the interval suggested in the table (<a href=\"image.htm?imageKey=PEDS%2F72640\" class=\"graphic graphic_table graphicRef72640 \">table 5</a>) [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/92\" class=\"abstract_t\">92</a>].</p><p class=\"headingAnchor\" id=\"H1787927920\"><span class=\"h2\">Current illness</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Whether MMR should be administered to children with current illness depends upon the severity of the illness:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Moderate to severe illness</strong> &ndash; We suggest that MMR be delayed in children with moderate to severe illness (eg, illnesses more severe than upper respiratory tract infection, otitis media, gastroenteritis), with or without fever, unless the vaccine is being administered for measles exposure (see <a href=\"#H1787930117\" class=\"local\">'Postexposure prophylaxis'</a> above). Delay of vaccination of children with moderate to severe illness avoids superimposing any adverse effects of the vaccine on the underlying illness and mistakenly attributing a manifestation of the underlying illness to the vaccine [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/1\" class=\"abstract_t\">1</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Mild illness</strong> &ndash; MMR and measles, mumps, rubella, and varicella combination vaccine (MMRV) can be safely administered to children with mild illness, with or without fever (eg, upper respiratory infection, otitis media, diarrhea); seroconversion is not affected by mild illness [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/93-95\" class=\"abstract_t\">93-95</a>]. Failure to vaccinate children with minor illnesses results in delayed immunization and increased duration of susceptibility [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/96\" class=\"abstract_t\">96</a>].</p><p/><p class=\"headingAnchor\" id=\"H1717312099\"><span class=\"h2\">Tuberculosis testing</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Tuberculin testing should be performed before, at the same visit as, or four to six weeks after MMR vaccination [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/1\" class=\"abstract_t\">1</a>]. MMR may temporarily reduce <a href=\"topic.htm?path=tuberculin-skin-test-drug-information\" class=\"drug drug_general\">tuberculin skin test</a> sensitivity [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/97\" class=\"abstract_t\">97</a>].</p><p>The effect of live virus vaccination on interferon-gamma release assay (IGRA) is uncertain [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/1\" class=\"abstract_t\">1</a>]. Pending additional information, the Advisory Committee on Immunization Practices (ACIP) suggests that IGRA testing be performed on the same day or four to six weeks after administration of MMR.</p><p class=\"headingAnchor\" id=\"H2313247094\"><span class=\"h2\">Antiviral medications</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Antiviral drugs active against herpesviruses (eg, <a href=\"topic.htm?path=acyclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">acyclovir</a>, <a href=\"topic.htm?path=valacyclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">valacyclovir</a>) may interfere with response to varicella-containing vaccines and should be discontinued &ge;24 hours before administration of varicella-containing vaccines [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/76\" class=\"abstract_t\">76</a>]. They also should and avoided for 14 days after vaccination.</p><p class=\"headingAnchor\" id=\"H1276242069\"><span class=\"h2\">HIV infection without severe immunosuppression</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For children with HIV infection who are not severely immunocompromised and have no evidence of measles, mumps, and rubella immunity, two doses of MMR should be administered [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/1,83,89\" class=\"abstract_t\">1,83,89</a>].</p><p>Absence of severe immunosuppression is defined according to age as follows:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>&le;5 years &ndash; CD4+ T lymphocyte (CD4) percentage is &ge;15 percent for at least six months; or, if CD4 percentage not available, CD4 count <span class=\"nowrap\">&ge;750/microL</span> for at least six months while &le;12 months of age or CD4 count <span class=\"nowrap\">&ge;500/microL</span> for at least six months while one through five years of age</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>&gt;5 years &ndash; CD4 percentage &ge;15 percent and CD4 count of <span class=\"nowrap\">&ge;200/microL</span> for at least six months if both tests are available; or, if only one test is available, CD4 percentage &ge;15 percent or CD4 count of <span class=\"nowrap\">&ge;200/microL</span></p><p/><p>MMRV is not recommended for HIV-infected children because it has not been studied in this population [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/83,89\" class=\"abstract_t\">83,89</a>].</p><p>Individuals with perinatal HIV infection who received MMR before 1996 (when effective antiretroviral therapy [ART] was established) may be at risk for measles, mumps, and rubella [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/98\" class=\"abstract_t\">98</a>]. Such individuals who do not have evidence of immunity to measles, mumps, and rubella should receive two doses of MMR, at least 28 days apart, once effective ART has been established [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/1\" class=\"abstract_t\">1</a>]. Effective ART is defined by receiving ART for &ge;6 months and lack of severe immunosuppression as defined above. The response to MMR is better in HIV-infected children who are receiving ART and have an undetectable viral load [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/99-101\" class=\"abstract_t\">99-101</a>].</p><p class=\"headingAnchor\" id=\"H1887040398\"><span class=\"h2\">Egg allergy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Egg allergy is <strong>not </strong>a contraindication to MMR or MMRV; these vaccines can be safely administered to children with egg allergy without prior skin testing or special protocols [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/1\" class=\"abstract_t\">1</a>]. (See <a href=\"topic.htm?path=allergic-reactions-to-vaccines#H22\" class=\"medical medical_review\">&quot;Allergic reactions to vaccines&quot;, section on 'Measles, mumps, and rubella'</a>.)</p><p class=\"headingAnchor\" id=\"H1276243661\"><span class=\"h2\">Immunocompromised contact</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>MMR can be given to children with immunocompromised household contacts, who are at increased risk for severe complications from natural measles infection [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/76,83\" class=\"abstract_t\">76,83</a>]. A 2007 literature review found no evidence of secondary transmission of measles, mumps, or rubella vaccine viruses from healthy vaccinees caring for or living with immunocompromised contacts [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/102\" class=\"abstract_t\">102</a>]. (See <a href=\"topic.htm?path=measles-clinical-manifestations-diagnosis-treatment-and-prevention#H9\" class=\"medical medical_review\">&quot;Measles: Clinical manifestations, diagnosis, treatment, and prevention&quot;, section on 'Complications'</a>.)</p><p class=\"headingAnchor\" id=\"H1787927943\"><span class=\"h2\">History of thrombocytopenia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Children with a history of thrombocytopenia or thrombocytopenic purpura may have an increased risk of clinically significant thrombocytopenia following immunization with MMR or MMRV [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/1\" class=\"abstract_t\">1</a>]. Decisions regarding administration of the <strong>first</strong> dose of MMR to children with a history of thrombocytopenia are made on a case-by-case basis contingent upon the assessment of risks and benefits. In many cases, the benefits outweigh the risks.</p><p>Factors to be considered in the decision include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Recurrence of thrombocytopenia following MMR in individuals with a history thrombocytopenia (both vaccine-associated and nonvaccine-associated) has been reported [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/103-106\" class=\"abstract_t\">103-106</a>], but the magnitude of the risk is unknown. In small series of children with a history of immune thrombocytopenic purpura, recurrences were not observed within six weeks of receipt of MMR [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/107-109\" class=\"abstract_t\">107-109</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The child's likelihood of exposure to measles, mumps, and rubella (eg, plans for international travel, level of MMR vaccination coverage in the child's school and community, etc).</p><p/><p>Serologic testing can be performed to determine whether the <strong>second</strong> dose of MMR is necessary. Children with protective levels of antibody to measles, mumps, and rubella do not need to receive the second dose. For children with a history of thrombocytopenia who lack protective levels of antibody to measles, mumps, or rubella, decisions regarding administration of the second dose of MMR are made on a case-by-case basis based upon the assessment of risks and benefits.</p><p class=\"headingAnchor\" id=\"H5659821\"><span class=\"h2\">Measles, mumps, or rubella infection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Children who have a history of measles, mumps, or rubella infection that was diagnosed without laboratory confirmation should be vaccinated as if they have not had infection [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/1\" class=\"abstract_t\">1</a>]. (See <a href=\"#H1787930105\" class=\"local\">'Routine immunization'</a> above.)</p><p>Children with laboratory confirmation of measles, mumps, or rubella disease are considered to be immune to that particular disease and need not be vaccinated against it. However, they generally receive two doses of MMR vaccine anyway because monovalent vaccines for measles, mumps, or rubella are no longer available in the United States. (See <a href=\"#H1276241676\" class=\"local\">'Vaccine formulations'</a> above.)</p><p class=\"headingAnchor\" id=\"H1787928038\"><span class=\"h2\">Personal or family history of seizures</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We suggest separate doses of MMR and <a href=\"topic.htm?path=varicella-virus-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">varicella vaccine</a> rather than MMRV for the first doses of MMR and varicella vaccine in children with a personal history of seizures or family history of seizures in a parent or sibling. (See <a href=\"#H1787931404\" class=\"local\">'Choice of vaccine'</a> above.)</p><p>Children with a personal or family history of seizures have an increased risk of febrile seizures following MMR [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/110,111\" class=\"abstract_t\">110,111</a>]. Although the increased risk of febrile seizure does not outweigh the benefits of immunization, the ACIP considers a personal or family history of febrile seizures to be a &quot;precaution&quot; for use of the combination MMRV for the first dose of measles, mumps, rubella, and varicella vaccines [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/1\" class=\"abstract_t\">1</a>].</p><p class=\"headingAnchor\" id=\"H1887040360\"><span class=\"h2\">Juvenile idiopathic arthritis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Immunization of children with juvenile idiopathic arthritis is discussed separately. (See <a href=\"topic.htm?path=oligoarticular-juvenile-idiopathic-arthritis#H1642734\" class=\"medical medical_review\">&quot;Oligoarticular juvenile idiopathic arthritis&quot;, section on 'Immunizations'</a>.)</p><p class=\"headingAnchor\" id=\"H1887040330\"><span class=\"h2\">International adoption</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Issues related to MMR immunization of children internationally adopted to the United States are discussed separately. (See <a href=\"topic.htm?path=international-adoption-immunization-considerations#H540328886\" class=\"medical medical_review\">&quot;International adoption: Immunization considerations&quot;, section on 'Immunizations for international adoptees'</a>.)</p><p class=\"headingAnchor\" id=\"H1276242324\"><span class=\"h1\">ADVERSE EFFECTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Adverse reactions to measles, mumps, and rubella combination vaccine (MMR) include fever, rash, lymphadenopathy, joint complaints, hypersensitivity reactions, development of immune thrombocytopenia (ITP), and seizures [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/112\" class=\"abstract_t\">112</a>]. These reactions occur more frequently with the first than with the second dose [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/113\" class=\"abstract_t\">113</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Fever (&gt;39.4&deg;C) develops in 5 to 15 percent of MMR recipients, usually within 6 to 12 days after immunization [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/54\" class=\"abstract_t\">54</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Transient rashes also occur in approximately 5 percent of MMR recipients [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/54\" class=\"abstract_t\">54</a>].</p><p/><p class=\"bulletIndent1\">The combination of fever and rash after MMR immunization generally is attributed to measles vaccine virus but may be due to wild-type measles or other viral illnesses [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/114\" class=\"abstract_t\">114</a>]; virologic studies may be warranted in children with potential exposure to wild type measles (eg, international travel, contact with immigrants).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Transient lymphadenopathy occurs in 5 percent of children and 20 percent of adults [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/1\" class=\"abstract_t\">1</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Joint complaints (secondary to the rubella component of the vaccine) may occur 7 to 21 days after MMR immunization [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/115\" class=\"abstract_t\">115</a>]. Joint pain, usually of small peripheral joints, has been reported in 0.5 percent of young children and arthralgia and transient arthritis in 25 and 10 percent of postpubertal females, respectively.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hypersensitivity reactions to the MMR are usually minor (wheal and flare, or urticaria) and have been attributed to trace amounts of <a href=\"topic.htm?path=neomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">neomycin</a> or gelatin but not to egg antigens, since MMR does not contain significant amounts of egg-white cross-reacting proteins [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/54,116,117\" class=\"abstract_t\">54,116,117</a>]. (See <a href=\"topic.htm?path=allergic-reactions-to-vaccines\" class=\"medical medical_review\">&quot;Allergic reactions to vaccines&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Although the risk of development of ITP in the six weeks after MMR vaccination is increased [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/107,118,119\" class=\"abstract_t\">107,118,119</a>], MMR-associated ITP is rare. In a 2010 systematic review that included 12 studies, the median incidence of ITP after MMR was 2.6 cases per 100,000 doses (range 0.87 to 4 cases per 100,000 doses) [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/120\" class=\"abstract_t\">120</a>]. This incidence is lower than the incidence of ITP after natural measles or rubella infection, and similar to the incidence of ITP in the general population. Thrombocytopenia resolved within six months in 93 percent of cases, and severe bleeding manifestations were rare. MMR vaccination was not associated with recurrence of thrombocytopenia in children with ITP (either MMR-associated or nonvaccine-associated). (See <a href=\"topic.htm?path=immune-thrombocytopenia-itp-in-children-clinical-features-and-diagnosis#H3\" class=\"medical medical_review\">&quot;Immune thrombocytopenia (ITP) in children: Clinical features and diagnosis&quot;, section on 'Epidemiology'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>MMR is associated with an increased risk of febrile seizures within 6 to 14 days of immunization (approximately one febrile seizure for every 3000 to 4000 doses of vaccine) [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/6,7\" class=\"abstract_t\">6,7</a>]. In a cohort of almost 680,000 children, the relative risk of febrile seizures 8 to 14 days after MMR immunization was 2.8 (95% CI 1.4-5.6) [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/6\" class=\"abstract_t\">6</a>]. There was no increased risk of nonfebrile seizures, and the children with febrile seizures after vaccination had no higher risk of subsequent seizure or neurodevelopmental disability than other children with febrile seizures in the absence of vaccine administration. Similar results were reported in another large cohort [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/110\" class=\"abstract_t\">110</a>]. In the second cohort, children with post-MMR febrile seizure had a slightly increased risk of recurrent febrile seizures (RR 1.2) but no increased risk of epilepsy, compared with children whose first febrile seizure was not associated with MMR. (See <a href=\"topic.htm?path=clinical-features-and-evaluation-of-febrile-seizures\" class=\"medical medical_review\">&quot;Clinical features and evaluation of febrile seizures&quot;</a>.)</p><p/><p class=\"bulletIndent1\">The risk of seizures in the 7 to 10 days after the first dose of measles-containing vaccine appears to be increased among children who receive the first dose between 16 and 23 months of age rather than at the recommended age of 12 to 15 months, highlighting the importance of timely administration of the first dose [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/30,31\" class=\"abstract_t\">30,31</a>]. (See <a href=\"#H1787930105\" class=\"local\">'Routine immunization'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>MMR does not appear to be associated with encephalopathy. In a retrospective case-control study including 452 children with encephalopathy and related conditions and up to three controls for each case, cases were no more likely than controls to have received MMR during the 90 days before onset of encephalopathy [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/121\" class=\"abstract_t\">121</a>].</p><p/><p class=\"headingAnchor\" id=\"H1276243182\"><span class=\"h1\">LACK OF ASSOCIATION WITH AUTISM</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Concern has been raised about a possible link between measles, mumps, and rubella vaccination and autism and other chronic diseases. Multiple studies have failed to demonstrate any such association. However, there is an association between congenital rubella syndrome and autism, highlighting a potential role for rubella immunization in the prevention of autism spectrum disorders [<a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/122\" class=\"abstract_t\">122</a>]. (See <a href=\"topic.htm?path=autism-spectrum-disorder-and-chronic-disease-no-evidence-for-vaccines-or-thimerosal-as-a-contributing-factor\" class=\"medical medical_review\">&quot;Autism spectrum disorder and chronic disease: No evidence for vaccines or thimerosal as a contributing factor&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1276243693\"><span class=\"h1\">RESOURCES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Resources related to immunization in infants and children include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The <a href=\"http://www2.aap.org/immunization/&amp;token=5tltgKjsh1mDbJyHG0NEojtvXxoObTwUE4bhWW2y6R5PmFJ4GgdEW+OFRbHHZuzi&amp;TOPIC_ID=101273\" target=\"_blank\" class=\"external\">American Academy of Pediatrics</a></p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The <a href=\"http://www.cdc.gov/vaccines&amp;token=mjmpv7xMHRIW2nr+3NCnsSvaFZCw29EzNp1VJ98rzB3WsW/rsom/FUgzOOnE2xVD&amp;TOPIC_ID=101273\" target=\"_blank\" class=\"external\">Centers for Disease Control and Prevention</a></p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The <a href=\"http://www.immunize.org/&amp;token=Xhpv4YrGbNrLf4iLM2FgO9OU7+srHa6FtzbbO0PYVVSvALUkLBSw0hah5bEtTSir&amp;TOPIC_ID=101273\" target=\"_blank\" class=\"external\">Immunization Action Coalition</a></p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.cdc.gov/vaccines/hcp/vis/index.html&amp;token=mjmpv7xMHRIW2nr+3NCnsUZAizKE5q1N5Y6YVyHCDVfrgN3OFnEkTiu2m/dNgvnyqGrqFJhUeNSLFcZIcP//1A==&amp;TOPIC_ID=101273\" target=\"_blank\" class=\"external\">Vaccine information statements for measles, mumps, and rubella vaccine and measles, mumps, rubella, and varicella vaccine</a></p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The <a href=\"http://www.who.int/topics/immunization/en/&amp;token=CGrU2PnO7/NB7T04m20ugKwaf5QtnqZBfsC5POl7g4DkdG8YXprQIT/6MNDENCYbjU15QcugNPWhWdCOdRo7qw==&amp;TOPIC_ID=101273\" target=\"_blank\" class=\"external\">World Health Organization</a></p><p/><p class=\"headingAnchor\" id=\"H3464286609\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-immunizations-in-children-and-adolescents\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Immunizations in children and adolescents&quot;</a>.)</p><p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\"><span class=\"h1\">INFORMATION FOR PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate offers two types of patient education materials, &quot;The Basics&quot; and &quot;Beyond the Basics.&quot; The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &quot;patient info&quot; and the keyword[s] of interest.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Basics topics (see <a href=\"topic.htm?path=measles-the-basics\" class=\"medical medical_basics\">&quot;Patient education: Measles (The Basics)&quot;</a> and <a href=\"topic.htm?path=mumps-the-basics\" class=\"medical medical_basics\">&quot;Patient education: Mumps (The Basics)&quot;</a> and <a href=\"topic.htm?path=rubella-the-basics\" class=\"medical medical_basics\">&quot;Patient education: Rubella (The Basics)&quot;</a> and <a href=\"topic.htm?path=vaccines-for-babies-and-children-age-0-to-6-years-the-basics\" class=\"medical medical_basics\">&quot;Patient education: Vaccines for babies and children age 0 to 6 years (The Basics)&quot;</a> and <a href=\"topic.htm?path=vaccines-for-children-age-7-to-18-years-the-basics\" class=\"medical medical_basics\">&quot;Patient education: Vaccines for children age 7 to 18 years (The Basics)&quot;</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Beyond the Basics topics (see <a href=\"topic.htm?path=why-does-my-child-need-vaccines-beyond-the-basics\" class=\"medical medical_patient\">&quot;Patient education: Why does my child need vaccines? (Beyond the Basics)&quot;</a> and <a href=\"topic.htm?path=vaccines-for-infants-and-children-age-0-to-6-years-beyond-the-basics\" class=\"medical medical_patient\">&quot;Patient education: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)&quot;</a> and <a href=\"topic.htm?path=vaccines-for-children-age-7-to-18-years-beyond-the-basics\" class=\"medical medical_patient\">&quot;Patient education: Vaccines for children age 7 to 18 years (Beyond the Basics)&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H1276243707\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We recommend measles, mumps, and rubella vaccination for United States children &ge;12 months of age (<a href=\"grade.htm?i=1\" class=\"grade\">Grade 1A</a>). We also recommend measles, mumps, and rubella vaccination for children who are &ge;6 months of age who live in or are traveling to areas where there is a measles outbreak or are traveling outside the United States (<a href=\"grade.htm?i=1\" class=\"grade\">Grade 1A</a>). In the United States, measles, mumps, and rubella combination vaccine (MMR) is typically administered at 12 through 15 months and 4 through 6 years of age (<a href=\"image.htm?imageKey=PEDS%2F82617\" class=\"graphic graphic_figure graphicRef82617 \">figure 1</a>). Schedules for other countries are available through the <a href=\"http://apps.who.int/immunization_monitoring/globalsummary&amp;token=OwnNIPPeGk/rbsSIEMq0IgOjNOv7VUbbhIG6Z6gMcV0Dql41+3EEqSmN6lmXxVXDaQVNaZmvR6hPn+vQ/s4dzQ==&amp;TOPIC_ID=101273\" target=\"_blank\" class=\"external\">World Health Organization</a>. (See <a href=\"#H1276243721\" class=\"local\">'Indications and schedules'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Catch-up MMR immunization is necessary for children who lack appropriate evidence of immunity or whose MMR immunization status is unknown. For most children, evidence of immunity requires documentation of two doses of measles- and mumps-containing vaccine, both administered at &ge;12 months of age and separated by &ge;28 days, and one dose of rubella-containing vaccine administered at &ge;12 months of age. The catch-up regimen varies with age, number of previous doses administered at &ge;12 months of age, and whether or not <a href=\"topic.htm?path=varicella-virus-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">varicella vaccine</a> is needed (<a href=\"image.htm?imageKey=PEDS%2F101591\" class=\"graphic graphic_table graphicRef101591 \">table 6</a>). (See <a href=\"#H1787930123\" class=\"local\">'Catch-up immunization'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The dose of MMR and MMR combined with <a href=\"topic.htm?path=varicella-virus-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">varicella vaccine</a> (MMRV) is 0.5 mL. MMR and MMRV are administered subcutaneously, usually in the upper outer triceps for children &ge;12 months of age and the lateral thigh for infants &lt;12 months of age. (See <a href=\"#H2313247273\" class=\"local\">'Administration'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Contraindications to MMR and MMRV vaccine include severe allergic reaction after a previous dose or to a vaccine component (eg, gelatin, <a href=\"topic.htm?path=neomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">neomycin</a>), pregnancy, and immunodeficiency (<a href=\"image.htm?imageKey=PEDS%2F101585\" class=\"graphic graphic_table graphicRef101585 \">table 4</a>). (See <a href=\"#H1787928363\" class=\"local\">'Contraindications'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Circumstances that may affect the timing of routine MMR immunization or choice of vaccine formulation include receipt of blood products or <a href=\"topic.htm?path=immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information\" class=\"drug drug_pediatric\">immune globulin</a> within the past 11 months; current illness more severe than upper respiratory infection, otitis media, or gastroenteritis; need for tuberculosis testing; antiviral medications; HIV infection without severe immunosuppression; and personal or family history of seizures (<a href=\"image.htm?imageKey=PEDS%2F101585\" class=\"graphic graphic_table graphicRef101585 \">table 4</a>). (See <a href=\"#H1276243647\" class=\"local\">'Special circumstances'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Multiple studies have failed to demonstrate any association between MMR and autism or other chronic diseases. (See <a href=\"topic.htm?path=autism-spectrum-disorder-and-chronic-disease-no-evidence-for-vaccines-or-thimerosal-as-a-contributing-factor\" class=\"medical medical_review\">&quot;Autism spectrum disorder and chronic disease: No evidence for vaccines or thimerosal as a contributing factor&quot;</a>.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/1\" class=\"nounderline abstract_t\">McLean HQ, Fiebelkorn AP, Temte JL, et al. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2013; 62:1.</a></li><li class=\"breakAll\">Centers for Disease Control and Prevention. Q &amp; As about monovalent M-M-R vaccines. Available at: www.cdc.gov/vaccines/vac-gen/shortages/mmr-faq-12-17-08.htm (Accessed on May 05, 2015).</li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/3\" class=\"nounderline abstract_t\">Low N, Bavdekar A, Jeyaseelan L, et al. A randomized, controlled trial of an aerosolized vaccine against measles. N Engl J Med 2015; 372:1519.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/4\" class=\"nounderline abstract_t\">Committee on Infectious Diseases. Policy statement&mdash;Prevention of varicella: update of recommendations for use of quadrivalent and monovalent varicella vaccines in children. Pediatrics 2011; 128:630.</a></li><li class=\"breakAll\">ProQuad measles, mumps, rubella, and varicella virus vaccine for subcutaneous injection. US Food &amp; Drug (FDA) approved product information. Revised March 2014. US National Library of Medicine. Available at: www.dailymed.nlm.nih.gov (Accessed on May 06, 2015).</li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/6\" class=\"nounderline abstract_t\">Barlow WE, Davis RL, Glasser JW, et al. The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. N Engl J Med 2001; 345:656.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/7\" class=\"nounderline abstract_t\">Farrington P, Pugh S, Colville A, et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet 1995; 345:567.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/8\" class=\"nounderline abstract_t\">Macartney K, Gidding HF, Trinh L, et al. Evaluation of Combination Measles-Mumps-Rubella-Varicella Vaccine Introduction in Australia. JAMA Pediatr 2017; 171:992.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/9\" class=\"nounderline abstract_t\">Jacobsen SJ, Ackerson BK, Sy LS, et al. Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting. Vaccine 2009; 27:4656.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/10\" class=\"nounderline abstract_t\">Klein NP, Fireman B, Yih WK, et al. Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. Pediatrics 2010; 126:e1.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/11\" class=\"nounderline abstract_t\">MacDonald SE, Dover DC, Simmonds KA, Svenson LW. Risk of febrile seizures after first dose of measles-mumps-rubella-varicella vaccine: a population-based cohort study. CMAJ 2014; 186:824.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/12\" class=\"nounderline abstract_t\">Klein NP, Lewis E, Baxter R, et al. Measles-containing vaccines and febrile seizures in children age 4 to 6 years. Pediatrics 2012; 129:809.</a></li><li class=\"breakAll\">Centers for Disease Control and Prevention. Varicella. In: Epidemiology and Prevention of Vaccine-Preventable Diseases. The Pink Book: Course Textbook, 13th ed, Hamborsky J, Kroger A, Wolfe S, (Eds). Public Health Foundation, Washington, DC 2015. http://www.cdc.gov/vaccines/pubs/pinkbook/index.html (Accessed on July 09, 2015).</li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/14\" class=\"nounderline abstract_t\">Redd SC, King GE, Heath JL, et al. Comparison of vaccination with measles-mumps-rubella vaccine at 9, 12, and 15 months of age. J Infect Dis 2004; 189 Suppl 1:S116.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/15\" class=\"nounderline abstract_t\">Carazo Perez S, De Serres G, Bureau A, Skowronski DM. Reduced antibody response to infant measles vaccination: effects based on type and timing of the first vaccine dose persist after the second dose. Clin Infect Dis 2017.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/16\" class=\"nounderline abstract_t\">LeBaron CW, Beeler J, Sullivan BJ, et al. Persistence of measles antibodies after 2 doses of measles vaccine in a postelimination environment. Arch Pediatr Adolesc Med 2007; 161:294.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/17\" class=\"nounderline abstract_t\">Davidkin I, Jokinen S, Broman M, et al. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up. J Infect Dis 2008; 197:950.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/18\" class=\"nounderline abstract_t\">Markowitz LE, Albrecht P, Orenstein WA, et al. Persistence of measles antibody after revaccination. J Infect Dis 1992; 166:205.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/19\" class=\"nounderline abstract_t\">Ward BJ, Boulianne N, Ratnam S, et al. Cellular immunity in measles vaccine failure: demonstration of measles antigen-specific lymphoproliferative responses despite limited serum antibody production after revaccination. J Infect Dis 1995; 172:1591.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/20\" class=\"nounderline abstract_t\">LeBaron CW, Forghani B, Matter L, et al. Persistence of rubella antibodies after 2 doses of measles-mumps-rubella vaccine. J Infect Dis 2009; 200:888.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/21\" class=\"nounderline abstract_t\">Hillary IB, Griffith AH. Persistence of rubella antibodies 15 years after subcutaneous administration of Wistar 27/3 strain live attenuated rubella virus vaccine. Vaccine 1984; 2:274.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/22\" class=\"nounderline abstract_t\">Christenson B, B&ouml;ttiger M. Long-term follow-up study of rubella antibodies in naturally immune and vaccinated young adults. Vaccine 1994; 12:41.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/23\" class=\"nounderline abstract_t\">LeBaron CW, Forghani B, Beck C, et al. Persistence of mumps antibodies after 2 doses of measles-mumps-rubella vaccine. J Infect Dis 2009; 199:552.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/24\" class=\"nounderline abstract_t\">Gothefors L, Bergstr&ouml;m E, Backman M. Immunogenicity and reactogenicity of a new measles, mumps and rubella vaccine when administered as a second dose at 12 y of age. Scand J Infect Dis 2001; 33:545.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/25\" class=\"nounderline abstract_t\">Broliden K, Abreu ER, Arneborn M, B&ouml;ttiger M. Immunity to mumps before and after MMR vaccination at 12 years of age in the first generation offered the two-dose immunization programme. Vaccine 1998; 16:323.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/26\" class=\"nounderline abstract_t\">Rodgers DV, Gindler JS, Atkinson WL, Markowitz LE. High attack rates and case fatality during a measles outbreak in groups with religious exemption to vaccination. Pediatr Infect Dis J 1993; 12:288.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/27\" class=\"nounderline abstract_t\">Centers for Disease Control (CDC). Measles outbreak--New York City, 1990-1991. MMWR Morb Mortal Wkly Rep 1991; 40:305.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/28\" class=\"nounderline abstract_t\">Centers for Disease Control (CDC). Measles outbreak--Washington, 1989: failure of delayed postexposure prophylaxis with vaccine. MMWR Morb Mortal Wkly Rep 1990; 39:617.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/29\" class=\"nounderline abstract_t\">Centers for Disease Control (CDC). Update: measles outbreak--Chicago, 1989. MMWR Morb Mortal Wkly Rep 1990; 39:317.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/30\" class=\"nounderline abstract_t\">Rowhani-Rahbar A, Fireman B, Lewis E, et al. Effect of age on the risk of Fever and seizures following immunization with measles-containing vaccines in children. JAMA Pediatr 2013; 167:1111.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/31\" class=\"nounderline abstract_t\">Hambidge SJ, Newcomer SR, Narwaney KJ, et al. Timely versus delayed early childhood vaccination and seizures. Pediatrics 2014; 133:e1492.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/32\" class=\"nounderline abstract_t\">Watson JC, Pearson JA, Markowitz LE, et al. An evaluation of measles revaccination among school-entry-aged children. Pediatrics 1996; 97:613.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/33\" class=\"nounderline abstract_t\">Poland GA, Jacobson RM, Thampy AM, et al. Measles reimmunization in children seronegative after initial immunization. JAMA 1997; 277:1156.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/34\" class=\"nounderline abstract_t\">Davis RL, Marcuse E, Black S, et al. MMR2 immunization at 4 to 5 years and 10 to 12 years of age: a comparison of adverse clinical events after immunization in the Vaccine Safety Datalink project. The Vaccine Safety Datalink Team. Pediatrics 1997; 100:767.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/35\" class=\"nounderline abstract_t\">Fiebelkorn AP, Coleman LA, Belongia EA, et al. Measles Virus Neutralizing Antibody Response, Cell-Mediated Immunity, and Immunoglobulin G Antibody Avidity Before and After Receipt of a Third Dose of Measles, Mumps, and Rubella Vaccine in Young Adults. J Infect Dis 2016; 213:1115.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/36\" class=\"nounderline abstract_t\">Demicheli V, Rivetti A, Debalini MG, Di Pietrantonj C. Vaccines for measles, mumps and rubella in children. Cochrane Database Syst Rev 2012; :CD004407.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/37\" class=\"nounderline abstract_t\">Centers for Disease Control and Prevention (CDC). Elimination of rubella and congenital rubella syndrome--United States, 1969-2004. MMWR Morb Mortal Wkly Rep 2005; 54:279.</a></li><li class=\"breakAll\">Pan American Health Organization. Americas region is declared the world's first to eliminate rubella. Available at: www.paho.org/hq/index.php?option=com_content&amp;view=article&amp;id=10798&amp;Itemid=1926&amp;lang=en (Accessed on May 01, 2015).</li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/39\" class=\"nounderline abstract_t\">Centers for Disease Control and Prevention (CDC). Three cases of congenital rubella syndrome in the postelimination era--Maryland, Alabama, and Illinois, 2012. MMWR Morb Mortal Wkly Rep 2013; 62:226.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/40\" class=\"nounderline abstract_t\">Centers for Disease Control and Prevention (CDC). Brief report: Imported case of congenital rubella syndrome--New Hampshire, 2005. MMWR Morb Mortal Wkly Rep 2005; 54:1160.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/41\" class=\"nounderline abstract_t\">Zipprich J, Winter K, Hacker J, et al. Measles outbreak--California, December 2014-February 2015. MMWR Morb Mortal Wkly Rep 2015; 64:153.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/42\" class=\"nounderline abstract_t\">Gahr P, DeVries AS, Wallace G, et al. An outbreak of measles in an undervaccinated community. Pediatrics 2014; 134:e220.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/43\" class=\"nounderline abstract_t\">Centers for Disease Control and Prevention (CDC). Notes from the field: measles outbreak among members of a religious community - Brooklyn, New York, March-June 2013. MMWR Morb Mortal Wkly Rep 2013; 62:752.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/44\" class=\"nounderline abstract_t\">Fiebelkorn AP, Redd SB, Gasta&ntilde;aduy PA, et al. A Comparison of Postelimination Measles Epidemiology in the United States, 2009-2014 Versus 2001-2008. J Pediatric Infect Dis Soc 2017; 6:40.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/45\" class=\"nounderline abstract_t\">Clemmons NS, Wallace GS, Patel M, Gasta&ntilde;aduy PA. Incidence of Measles in the United States, 2001-2015. JAMA 2017; 318:1279.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/46\" class=\"nounderline abstract_t\">Holt EA, Boulos R, Halsey NA, et al. Childhood survival in Haiti: protective effect of measles vaccination. Pediatrics 1990; 85:188.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/47\" class=\"nounderline abstract_t\">Kabir Z, Long J, Reddaiah VP, et al. Non-specific effect of measles vaccination on overall child mortality in an area of rural India with high vaccination coverage: a population-based case-control study. Bull World Health Organ 2003; 81:244.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/48\" class=\"nounderline abstract_t\">Koenig MA, Khan MA, Wojtyniak B, et al. Impact of measles vaccination on childhood mortality in rural Bangladesh. Bull World Health Organ 1990; 68:441.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/49\" class=\"nounderline abstract_t\">Clemens JD, Stanton BF, Chakraborty J, et al. Measles vaccination and childhood mortality in rural Bangladesh. Am J Epidemiol 1988; 128:1330.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/50\" class=\"nounderline abstract_t\">Desgr&eacute;es du Lo&ucirc; A, Pison G, Aaby P. Role of immunizations in the recent decline in childhood mortality and the changes in the female/male mortality ratio in rural Senegal. Am J Epidemiol 1995; 142:643.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/51\" class=\"nounderline abstract_t\">Fisker AB, Rodrigues A, Martins C, et al. Reduced All-cause Child Mortality After General Measles Vaccination Campaign in Rural Guinea-Bissau. Pediatr Infect Dis J 2015; 34:1369.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/52\" class=\"nounderline abstract_t\">Mina MJ, Metcalf CJ, de Swart RL, et al. Long-term measles-induced immunomodulation increases overall childhood infectious disease mortality. Science 2015; 348:694.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/53\" class=\"nounderline abstract_t\">de Vries RD, de Swart RL. Measles immune suppression: functional impairment or numbers game? PLoS Pathog 2014; 10:e1004482.</a></li><li class=\"breakAll\">American Academy of Pediatrics. Measles. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30th ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2015. p.535.</li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/55\" class=\"nounderline abstract_t\">van der Maas NA, Woudenberg T, Hahn&eacute; SJ, de Melker HE. Tolerability of Early Measles-Mumps-Rubella Vaccination in Infants Aged 6-14 Months During a Measles Outbreak in The Netherlands in 2013-2014. J Infect Dis 2016; 213:1466.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/56\" class=\"nounderline abstract_t\">Hutchins SS, Dezayas A, Le Blond K, et al. Evaluation of an early two-dose measles vaccination schedule. Am J Epidemiol 2001; 154:1064.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/57\" class=\"nounderline abstract_t\">Woudenberg T, van der Maas NAT, Knol MJ, et al. Effectiveness of Early Measles, Mumps, and Rubella Vaccination Among 6-14-Month-Old Infants During an Epidemic in the Netherlands: An Observational Cohort Study. J Infect Dis 2017; 215:1181.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/58\" class=\"nounderline abstract_t\">Woo EJ, Winiecki SK, Arya D, Beeler J. Adverse Events After MMR or MMRV Vaccine in Infants Under Nine Months Old. Pediatr Infect Dis J 2016; 35:e253.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/59\" class=\"nounderline abstract_t\">Marin M, Marlow M, Moore KL, Patel M. Recommendation of the Advisory Committee on Immunization Practices for Use of a Third Dose of Mumps Virus-Containing Vaccine in Persons at Increased Risk for Mumps During an Outbreak. MMWR Morb Mortal Wkly Rep 2018; 67:33.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/60\" class=\"nounderline abstract_t\">Lejeune A, Martin L, Santibanez S, et al. Postexposure prophylaxis with intravenous immunoglobulin G prevents infants from getting measles. Acta Paediatr 2017; 106:174.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/61\" class=\"nounderline abstract_t\">Arciuolo RJ, Jablonski RR, Zucker JR, Rosen JB. Effectiveness of Measles Vaccination and Immune Globulin Post-Exposure Prophylaxis in an Outbreak Setting-New York City, 2013. Clin Infect Dis 2017; 65:1843.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/62\" class=\"nounderline abstract_t\">Sheppeard V, Forssman B, Ferson MJ, et al. The effectiveness of prophylaxis for measles contacts in NSW. N S W Public Health Bull 2009; 20:81.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/63\" class=\"nounderline abstract_t\">Barrabeig I, Rovira A, Rius C, et al. Effectiveness of measles vaccination for control of exposed children. Pediatr Infect Dis J 2011; 30:78.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/64\" class=\"nounderline abstract_t\">Young MK, Nimmo GR, Cripps AW, Jones MA. Post-exposure passive immunisation for preventing measles. Cochrane Database Syst Rev 2014; :CD010056.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/65\" class=\"nounderline abstract_t\">Bigham M, Murti M, Fung C, et al. Estimated protective effectiveness of intramuscular immune serum globulin post-exposure prophylaxis during a measles outbreak in British Columbia, Canada, 2014. Vaccine 2017; 35:2723.</a></li><li class=\"breakAll\">Centers for Disease Control and Prevention. Mumps In: Epidemiology and Prevention of Vaccine-Preventable Diseases. The Pink Book: Course Textbook, 13th ed, Hamborsky J, Kroger A, Wolfe S, (Eds). Public Health Foundation, Washington, DC 2015. http://www.cdc.gov/vaccines/pubs/pinkbook/index.html (Accessed on November 25, 2016).</li><li class=\"breakAll\">Centers for Disease Control and Prevention. Rubella. In: Epidemiology and Prevention of Vaccine-Preventable Diseases. The Pink Book: Course Textbook, 13th ed, Hamborsky J, Kroger A, Wolfe S, (Eds). Public Health Foundation, Washington, DC 2015. http://www.cdc.gov/vaccines/pubs/pinkbook/index.html (Accessed on November 25, 2016).</li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/68\" class=\"nounderline abstract_t\">Salzman MB, Cherry JD. Effectiveness of Intramuscular Immunoglobulin in Unvaccinated Family Members After Household Measles Exposure. Clin Infect Dis 2017; 65:1955.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/69\" class=\"nounderline abstract_t\">Ogbuanu IU, Kutty PK, Hudson JM, et al. Impact of a third dose of measles-mumps-rubella vaccine on a mumps outbreak. Pediatrics 2012; 130:e1567.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/70\" class=\"nounderline abstract_t\">Nelson GE, Aguon A, Valencia E, et al. Epidemiology of a mumps outbreak in a highly vaccinated island population and use of a third dose of measles-mumps-rubella vaccine for outbreak control--Guam 2009 to 2010. Pediatr Infect Dis J 2013; 32:374.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/71\" class=\"nounderline abstract_t\">Date AA, Kyaw MH, Rue AM, et al. Long-term persistence of mumps antibody after receipt of 2 measles-mumps-rubella (MMR) vaccinations and antibody response after a third MMR vaccination among a university population. J Infect Dis 2008; 197:1662.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/72\" class=\"nounderline abstract_t\">Measles vaccines: WHO position paper &ndash; April 2017. Wkly Epidemiol Rec 2017; 92:205.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/73\" class=\"nounderline abstract_t\">Mumps virus vaccines. Wkly Epidemiol Rec 2007; 82:51.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/74\" class=\"nounderline abstract_t\">Rubella vaccines: WHO position paper. Wkly Epidemiol Rec 2011; 86:301.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/75\" class=\"nounderline abstract_t\">Patel MK, Gacic-Dobo M, Strebel PM, et al. Progress Toward Regional Measles Elimination - Worldwide, 2000-2015. MMWR Morb Mortal Wkly Rep 2016; 65:1228.</a></li><li class=\"breakAll\">Kroger AT, Duchin J, V&aacute;zquez M. General best practice guidelines for immunization. Best practices guidance of the Advisory Committee on Immunization Practices (ACIP). Available at: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html (Accessed on April 27, 2017).</li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/77\" class=\"nounderline abstract_t\">Knuf M, Zepp F, Meyer CU, et al. Safety, immunogenicity and immediate pain of intramuscular versus subcutaneous administration of a measles-mumps-rubella-varicella vaccine to children aged 11-21 months. Eur J Pediatr 2010; 169:925.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/78\" class=\"nounderline abstract_t\">Cassidy WM, Jones G, Williams K, et al. Safety and immunogenicity of concomitant versus nonconcomitant administration of hepatitis B, tetanus-diphtheria, and measles-mumps-rubella vaccines in healthy eleven- to twelve-year-olds. J Adolesc Health 2005; 36:187.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/79\" class=\"nounderline abstract_t\">Gasparini R, Tregnaghi M, Keshavan P, et al. Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine and Commonly Administered Vaccines After Coadministration. Pediatr Infect Dis J 2016; 35:81.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/80\" class=\"nounderline abstract_t\">PETRALLI JK, MERIGAN TC, WILBUR JR. ACTION OF ENDOGENOUS INTERFERON AGAINST VACCINIA INFECTION IN CHILDREN. Lancet 1965; 2:401.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/81\" class=\"nounderline abstract_t\">PETRALLI JK, MERIGAN TC, WILBUR JR. CIRCULATING INTERFERON AFTER MEASLES VACCINATION. N Engl J Med 1965; 273:198.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/82\" class=\"nounderline abstract_t\">Verstraeten T, Jumaan AO, Mullooly JP, et al. A retrospective cohort study of the association of varicella vaccine failure with asthma, steroid use, age at vaccination, and measles-mumps-rubella vaccination. Pediatrics 2003; 112:e98.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/83\" class=\"nounderline abstract_t\">Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014; 58:e44.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/84\" class=\"nounderline abstract_t\">Poon TP, Tchertkoff V, Win H. Subacute measles encephalitis with AIDS diagnosed by fine needle aspiration biopsy. A case report. Acta Cytol 1998; 42:729.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/85\" class=\"nounderline abstract_t\">Bitnun A, Shannon P, Durward A, et al. Measles inclusion-body encephalitis caused by the vaccine strain of measles virus. Clin Infect Dis 1999; 29:855.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/86\" class=\"nounderline abstract_t\">Baram TZ, Gonzalez-Gomez I, Xie ZD, et al. Subacute sclerosing panencephalitis in an infant: diagnostic role of viral genome analysis. Ann Neurol 1994; 36:103.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/87\" class=\"nounderline abstract_t\">Centers for Disease Control and Prevention (CDC). Measles pneumonitis following measles-mumps-rubella vaccination of a patient with HIV infection, 1993. MMWR Morb Mortal Wkly Rep 1996; 45:603.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/88\" class=\"nounderline abstract_t\">Derryck A, LaRussa P, Steinberg S, et al. Varicella and zoster in children with human immunodeficiency virus infection. Pediatr Infect Dis J 1998; 17:931.</a></li><li class=\"breakAll\">Department of Health and Human Services. Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children. Available at: aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf (Accessed on November 20, 2013).</li><li class=\"breakAll\">American Academy of Pediatrics. Immunization in immunocompromised children. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30th ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, 2015. p.74.</li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/91\" class=\"nounderline abstract_t\">Siber GR, Werner BG, Halsey NA, et al. Interference of immune globulin with measles and rubella immunization. J Pediatr 1993; 122:204.</a></li><li class=\"breakAll\">American Academy of Pediatrics. Active immunization of people who recently received immune globulin and other blood products. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30th ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2015. p.38.</li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/93\" class=\"nounderline abstract_t\">King GE, Markowitz LE, Heath J, et al. Antibody response to measles-mumps-rubella vaccine of children with mild illness at the time of vaccination. JAMA 1996; 275:704.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/94\" class=\"nounderline abstract_t\">Dennehy PH, Saracen CL, Peter G. Seroconversion rates to combined measles-mumps-rubella-varicella vaccine of children with upper respiratory tract infection. Pediatrics 1994; 94:514.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/95\" class=\"nounderline abstract_t\">Ratnam S, West R, Gadag V. Measles and rubella antibody response after measles-mumps-rubella vaccination in children with afebrile upper respiratory tract infection. J Pediatr 1995; 127:432.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/96\" class=\"nounderline abstract_t\">Farizo KM, Stehr-Green PA, Markowitz LE, Patriarca PA. Vaccination levels and missed opportunities for measles vaccination: a record audit in a public pediatric clinic. Pediatrics 1992; 89:589.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/97\" class=\"nounderline abstract_t\">Brickman HF, Beaudry PH, Marks MI. The timing of tuberculin tests in relation to immunization with live viral vaccines. Pediatrics 1975; 55:392.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/98\" class=\"nounderline abstract_t\">Siberry GK, Patel K, Bellini WJ, et al. Immunity to Measles, Mumps, and Rubella in US Children With Perinatal HIV Infection or Perinatal HIV Exposure Without Infection. Clin Infect Dis 2015; 61:988.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/99\" class=\"nounderline abstract_t\">Berkelhamer S, Borock E, Elsen C, et al. Effect of highly active antiretroviral therapy on the serological response to additional measles vaccinations in human immunodeficiency virus-infected children. Clin Infect Dis 2001; 32:1090.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/100\" class=\"nounderline abstract_t\">Aurpibul L, Puthanakit T, Sirisanthana T, Sirisanthana V. Response to measles, mumps, and rubella revaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy. Clin Infect Dis 2007; 45:637.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/101\" class=\"nounderline abstract_t\">Rowson K, Tan A, Donaghy S, et al. Measles reimmunization may not be effective in protecting HIV-infected children. Pediatr Infect Dis J 2015; 34:552.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/102\" class=\"nounderline abstract_t\">Kamboj M, Sepkowitz KA. Risk of transmission associated with live attenuated vaccines given to healthy persons caring for or residing with an immunocompromised patient. Infect Control Hosp Epidemiol 2007; 28:702.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/103\" class=\"nounderline abstract_t\">Nieminen U, Peltola H, Syrj&auml;l&auml; MT, et al. Acute thrombocytopenic purpura following measles, mumps and rubella vaccination. A report on 23 patients. Acta Paediatr 1993; 82:267.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/104\" class=\"nounderline abstract_t\">Beeler J, Varricchio F, Wise R. Thrombocytopenia after immunization with measles vaccines: review of the vaccine adverse events reporting system (1990 to 1994). Pediatr Infect Dis J 1996; 15:88.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/105\" class=\"nounderline abstract_t\">Drachtman RA, Murphy S, Ettinger LJ. Exacerbation of chronic idiopathic thrombocytopenic purpura following measles-mumps-rubella immunization. Arch Pediatr Adolesc Med 1994; 148:326.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/106\" class=\"nounderline abstract_t\">Vlacha V, Forman EN, Miron D, Peter G. Recurrent thrombocytopenic purpura after repeated measles-mumps-rubella vaccination. Pediatrics 1996; 97:738.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/107\" class=\"nounderline abstract_t\">France EK, Glanz J, Xu S, et al. Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children. Pediatrics 2008; 121:e687.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/108\" class=\"nounderline abstract_t\">Miller E, Waight P, Farrington CP, et al. Idiopathic thrombocytopenic purpura and MMR vaccine. Arch Dis Child 2001; 84:227.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/109\" class=\"nounderline abstract_t\">Stowe J, Kafatos G, Andrews N, Miller E. Idiopathic thrombocytopenic purpura and the second dose of MMR. Arch Dis Child 2008; 93:182.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/110\" class=\"nounderline abstract_t\">Vestergaard M, Hviid A, Madsen KM, et al. MMR vaccination and febrile seizures: evaluation of susceptible subgroups and long-term prognosis. JAMA 2004; 292:351.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/111\" class=\"nounderline abstract_t\">Berg AT, Shinnar S, Shapiro ED, et al. Risk factors for a first febrile seizure: a matched case-control study. Epilepsia 1995; 36:334.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/112\" class=\"nounderline abstract_t\">Kuter BJ, Brown M, Wiedmann RT, et al. Safety and Immunogenicity of M-M-RII (Combination Measles-Mumps-Rubella Vaccine) in Clinical Trials of Healthy Children Conducted Between 1988 and 2009. Pediatr Infect Dis J 2016; 35:1011.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/113\" class=\"nounderline abstract_t\">LeBaron CW, Bi D, Sullivan BJ, et al. Evaluation of potentially common adverse events associated with the first and second doses of measles-mumps-rubella vaccine. Pediatrics 2006; 118:1422.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/114\" class=\"nounderline abstract_t\">Ting CY, Tee NW, Thoon KC. Could a fever and rash after the measles, mumps and rubella vaccination indicate wild-type measles? Acta Paediatr 2015; 104:e232.</a></li><li class=\"breakAll\">American Academy of Pediatrics. Rubella. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30th ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2015. p.688.</li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/116\" class=\"nounderline abstract_t\">James JM, Burks AW, Roberson PK, Sampson HA. Safe administration of the measles vaccine to children allergic to eggs. N Engl J Med 1995; 332:1262.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/117\" class=\"nounderline abstract_t\">Beck SA, Williams LW, Shirrell MA, Burks AW. Egg hypersensitivity and measles-mumps-rubella vaccine administration. Pediatrics 1991; 88:913.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/118\" class=\"nounderline abstract_t\">O'Leary ST, Glanz JM, McClure DL, et al. The risk of immune thrombocytopenic purpura after vaccination in children and adolescents. Pediatrics 2012; 129:248.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/119\" class=\"nounderline abstract_t\">Klein NP, Lewis E, Fireman B, et al. Safety of measles-containing vaccines in 1-year-old children. Pediatrics 2015; 135:e321.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/120\" class=\"nounderline abstract_t\">Mantadakis E, Farmaki E, Buchanan GR. Thrombocytopenic purpura after measles-mumps-rubella vaccination: a systematic review of the literature and guidance for management. J Pediatr 2010; 156:623.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/121\" class=\"nounderline abstract_t\">Ray P, Hayward J, Michelson D, et al. Encephalopathy after whole-cell pertussis or measles vaccination: lack of evidence for a causal association in a retrospective case-control study. Pediatr Infect Dis J 2006; 25:768.</a></li><li><a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-immunization-in-infants-children-and-adolescents/abstract/122\" class=\"nounderline abstract_t\">Chess S, Fernandez P, Korn S. Behavioral consequences of congenital rubella. J Pediatr 1978; 93:699.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 101273 Version 33.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H1276243707\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1276243470\" id=\"outline-link-H1276243470\">INTRODUCTION</a></li><li><a href=\"#H1276241566\" id=\"outline-link-H1276241566\">MEASLES, MUMPS, AND RUBELLA INFECTIONS</a></li><li><a href=\"#H1276241676\" id=\"outline-link-H1276241676\">VACCINE FORMULATIONS</a></li><li><a href=\"#H1787931404\" id=\"outline-link-H1787931404\">CHOICE OF VACCINE</a></li><li><a href=\"#H1276243721\" id=\"outline-link-H1276243721\">INDICATIONS AND SCHEDULES</a><ul><li><a href=\"#H1787929993\" id=\"outline-link-H1787929993\">United States</a><ul><li><a href=\"#H1787930105\" id=\"outline-link-H1787930105\">- Routine immunization</a></li><li><a href=\"#H1787932314\" id=\"outline-link-H1787932314\">- Outbreaks and international travel</a></li><li><a href=\"#H1787930117\" id=\"outline-link-H1787930117\">- Postexposure prophylaxis</a></li><li><a href=\"#H1787930123\" id=\"outline-link-H1787930123\">- Catch-up immunization</a></li></ul></li><li><a href=\"#H1787929999\" id=\"outline-link-H1787929999\">Other countries</a></li></ul></li><li><a href=\"#H2313247273\" id=\"outline-link-H2313247273\">ADMINISTRATION</a></li><li><a href=\"#H1787928363\" id=\"outline-link-H1787928363\">CONTRAINDICATIONS</a></li><li><a href=\"#H1276243647\" id=\"outline-link-H1276243647\">SPECIAL CIRCUMSTANCES</a><ul><li><a href=\"#H1276241973\" id=\"outline-link-H1276241973\">Recent receipt of blood or immune globulin</a></li><li><a href=\"#H1787927920\" id=\"outline-link-H1787927920\">Current illness</a></li><li><a href=\"#H1717312099\" id=\"outline-link-H1717312099\">Tuberculosis testing</a></li><li><a href=\"#H2313247094\" id=\"outline-link-H2313247094\">Antiviral medications</a></li><li><a href=\"#H1276242069\" id=\"outline-link-H1276242069\">HIV infection without severe immunosuppression</a></li><li><a href=\"#H1887040398\" id=\"outline-link-H1887040398\">Egg allergy</a></li><li><a href=\"#H1276243661\" id=\"outline-link-H1276243661\">Immunocompromised contact</a></li><li><a href=\"#H1787927943\" id=\"outline-link-H1787927943\">History of thrombocytopenia</a></li><li><a href=\"#H5659821\" id=\"outline-link-H5659821\">Measles, mumps, or rubella infection</a></li><li><a href=\"#H1787928038\" id=\"outline-link-H1787928038\">Personal or family history of seizures</a></li><li><a href=\"#H1887040360\" id=\"outline-link-H1887040360\">Juvenile idiopathic arthritis</a></li><li><a href=\"#H1887040330\" id=\"outline-link-H1887040330\">International adoption</a></li></ul></li><li><a href=\"#H1276242324\" id=\"outline-link-H1276242324\">ADVERSE EFFECTS</a></li><li><a href=\"#H1276243182\" id=\"outline-link-H1276243182\">LACK OF ASSOCIATION WITH AUTISM</a></li><li><a href=\"#H1276243693\" id=\"outline-link-H1276243693\">RESOURCES</a></li><li><a href=\"#H3464286609\" id=\"outline-link-H3464286609\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#PATIENT_INFORMATION\" id=\"outline-link-H1276243700\">INFORMATION FOR PATIENTS</a></li><li><a href=\"#H1276243707\" id=\"outline-link-H1276243707\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"PEDS/101273|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=PEDS/82617\" class=\"graphic graphic_figure\">- Childhood immunization schedule 0 through 6 years</a></li><li><a href=\"image.htm?imageKey=PEDS/101586\" class=\"graphic graphic_figure\">- Measles epidemiology US</a></li><li><a href=\"image.htm?imageKey=PEDS/101590\" class=\"graphic graphic_figure\">- Mumps epidemiology US</a></li><li><a href=\"image.htm?imageKey=PEDS/70446\" class=\"graphic graphic_figure\">- Rubella CRS epidemiology US</a></li></ul></li><li><div id=\"PEDS/101273|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=ID/57093\" class=\"graphic graphic_picture\">- Truncal rash in measles</a></li><li><a href=\"image.htm?imageKey=ID/57803\" class=\"graphic graphic_picture\">- Boy with measles</a></li><li><a href=\"image.htm?imageKey=ID/57571\" class=\"graphic graphic_picture\">- Koplik spots in measles</a></li><li><a href=\"image.htm?imageKey=ID/53503\" class=\"graphic graphic_picture\">- Parotid gland swelling</a></li><li><a href=\"image.htm?imageKey=ID/61263\" class=\"graphic graphic_picture\">- Rubella rash</a></li><li><a href=\"image.htm?imageKey=PEDS/64979\" class=\"graphic graphic_picture\">- Congenital rubella cataract</a></li></ul></li><li><div id=\"PEDS/101273|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=PEDS/101587\" class=\"graphic graphic_table\">- MMR and MMRV storage requirements</a></li><li><a href=\"image.htm?imageKey=PEDS/65930\" class=\"graphic graphic_table\">- MMRV febrile seizure risk</a></li><li><a href=\"image.htm?imageKey=PEDS/101589\" class=\"graphic graphic_table\">- MMR seroconversion and effectiveness</a></li><li><a href=\"image.htm?imageKey=PEDS/101585\" class=\"graphic graphic_table\">- MMR contraindications and precautions</a></li><li><a href=\"image.htm?imageKey=PEDS/72640\" class=\"graphic graphic_table\">- MMR and VZV in immune globulin or blood product recipients</a></li><li><a href=\"image.htm?imageKey=PEDS/101591\" class=\"graphic graphic_table\">- MMR catch-up schedule</a></li><li><a href=\"image.htm?imageKey=ID/112956\" class=\"graphic graphic_table\">- Live vaccines</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=allergic-reactions-to-vaccines\" class=\"medical medical_review\">Allergic reactions to vaccines</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=autism-spectrum-disorder-and-chronic-disease-no-evidence-for-vaccines-or-thimerosal-as-a-contributing-factor\" class=\"medical medical_review\">Autism spectrum disorder and chronic disease: No evidence for vaccines or thimerosal as a contributing factor</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-features-and-evaluation-of-febrile-seizures\" class=\"medical medical_review\">Clinical features and evaluation of febrile seizures</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=congenital-rubella-syndrome-clinical-features-and-diagnosis\" class=\"medical medical_review\">Congenital rubella syndrome: Clinical features and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=immune-thrombocytopenia-itp-in-children-clinical-features-and-diagnosis\" class=\"medical medical_review\">Immune thrombocytopenia (ITP) in children: Clinical features and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=immunizations-during-pregnancy\" class=\"medical medical_review\">Immunizations during pregnancy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=immunizations-for-travel\" class=\"medical medical_review\">Immunizations for travel</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=immunizations-in-adults-with-cancer\" class=\"medical medical_review\">Immunizations in adults with cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=immunizations-in-hematopoietic-cell-transplant-candidates-and-recipients\" class=\"medical medical_review\">Immunizations in hematopoietic cell transplant candidates and recipients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=immunizations-in-solid-organ-transplant-candidates-and-recipients\" class=\"medical medical_review\">Immunizations in solid organ transplant candidates and recipients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=international-adoption-immunization-considerations\" class=\"medical medical_review\">International adoption: Immunization considerations</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=measles-mumps-and-rubella-immunization-in-adults\" class=\"medical medical_review\">Measles, mumps, and rubella immunization in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=measles-clinical-manifestations-diagnosis-treatment-and-prevention\" class=\"medical medical_review\">Measles: Clinical manifestations, diagnosis, treatment, and prevention</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=measles-epidemiology-and-transmission\" class=\"medical medical_review\">Measles: Epidemiology and transmission</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=mumps\" class=\"medical medical_review\">Mumps</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=oligoarticular-juvenile-idiopathic-arthritis\" class=\"medical medical_review\">Oligoarticular juvenile idiopathic arthritis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=measles-the-basics\" class=\"medical medical_basics\">Patient education: Measles (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=mumps-the-basics\" class=\"medical medical_basics\">Patient education: Mumps (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=rubella-the-basics\" class=\"medical medical_basics\">Patient education: Rubella (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=vaccines-for-babies-and-children-age-0-to-6-years-the-basics\" class=\"medical medical_basics\">Patient education: Vaccines for babies and children age 0 to 6 years (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=vaccines-for-children-age-7-to-18-years-beyond-the-basics\" class=\"medical medical_patient\">Patient education: Vaccines for children age 7 to 18 years (Beyond the Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=vaccines-for-children-age-7-to-18-years-the-basics\" class=\"medical medical_basics\">Patient education: Vaccines for children age 7 to 18 years (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=vaccines-for-infants-and-children-age-0-to-6-years-beyond-the-basics\" class=\"medical medical_patient\">Patient education: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=why-does-my-child-need-vaccines-beyond-the-basics\" class=\"medical medical_patient\">Patient education: Why does my child need vaccines? (Beyond the Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=rubella\" class=\"medical medical_review\">Rubella</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=rubella-in-pregnancy\" class=\"medical medical_review\">Rubella in pregnancy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-immunizations-in-children-and-adolescents\" class=\"medical medical_society_guidelines\">Society guideline links: Immunizations in children and adolescents</a></li></ul></div></div>","javascript":null}